Diagnocure Acquires Rights to Breast Cancer Markers

A worldwide exclusive license to new protein technology for the detection of breast cancer has been acquired by Diagnocure, Inc. (Quebec City, Canada) from McGill University (Montreal, Canada). Under the terms of the agreement, Diagnocure's rights to this technology also extend to the detection of any other cancer.

A research team at McGill, working with collaborators at the University of Manitoba (Canada) and the University of California at San Francisco (USA), has shown that the CDP/Cux proteins are abnormally expressed in some breast cancers and could contribute to the development of this cancer. Breast cancer is the most common malignancy among women, and incidence rates are increasing in women who are 50 or older.

"The detection of the CDP/Cux proteins is expected to provide important information at the time of diagnosis because its elevated expression occurs early during cancer development,” stated Dr. Alain Nepveu, professor in the departments of medicine, biochemistry, and oncology at McGill University.

"We intend, through our developmental expertise and our nucleic acid amplification and antibody-based technology platforms, to potentially develop different diagnostic approaches to breast cancer detection,” said Pierre Desy, president and CEO of DiagnoCure.



Related Links:
DiagnoCure
McGill U.